002513.SHE Jiangsu Lanfeng Bio-chemical Co Ltd
- Market cap
- CNY 1.66B
- P/E
- -
- P/B
- 353.85x
- ROE
- -
- Dividend yield
- 1.97%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002513.SHE undervalued?
Graham numberThe Graham number of Jiangsu Lanfeng Bio-chemical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Lanfeng Bio-chemical Co Ltd fundamental analysis
No fundamental analysis for Jiangsu Lanfeng Bio-chemical Co Ltd yet.
Jiangsu Lanfeng Bio-chemical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Lanfeng Bio-chemical Co Ltd
Jiangsu Lanfeng Bio-chemical Co.,Ltd engages in the production and processing of fungicide, insecticide, herbicide technicals and formulations, and chemical products in China and internationally. It offers carbendazim, thiophanate, fluticasone, benzoyl, cymoxanil, iprodione, imidacloprid, acetamiprid, pyrethroid, pyridaben, butylene, acetaminophen, lego, cycloazine, thiophanate-methyl, butylcarbofuran, cycloazine, sulfuric acid, and surfactants. The company is also involved …
Full company profileJiangsu Lanfeng Bio-chemical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangsu Lanfeng Bio-chemical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.46B | 1.85B | 1.48B | 1.50B | 1.34B | 1.44B | 1.45B | 1.74B | 1.79B | 2.34B | 2.39B |
| Gross Profit | 484M | 562M | 322M | 315M | 179M | -29.2M | -7.12M | -63.2M | -108M | 73.3M | 39.3M |
| Operating Income | 107M | 76.7M | -926M | -559M | -6.93M | -532M | -180M | -347M | -404M | -135M | -178M |
| EBITDA | 321M | 269M | -697M | -361M | 161M | -394M | -134M | -227M | -251M | -96.2M | -251M |
| Net Income | 107M | 35.4M | -875M | -517M | 14.8M | -491M | -321M | -332M | -253M | -191M | -140M |
| EPS | 0.32 | 0.10 | -2.57 | -1.52 | 0.04 | -1.44 | -0.86 | -0.89 | -0.68 | -0.51 | -0.37 |
| Balance Sheet | |||||||||||
| Total Assets | 4.05B | 4.03B | 3.53B | 2.70B | 2.31B | 1.73B | 1.48B | 3.40B | 3.42B | 4.48B | 3.98B |
| Total Liabilities | 1.54B | 1.50B | 1.87B | 1.57B | 1.15B | 1.06B | 1.12B | 3.15B | 3.11B | 4.12B | 3.74B |
| Shareholders' Equity | 2.51B | 2.53B | 1.66B | 1.14B | 1.16B | 667M | 358M | 25.2M | 32.5M | 43.7M | -18.3M |
| Cash & Short-term Investments | 489M | 246M | 582M | 280M | 331M | 84.6M | 24.0M | 457M | 408M | 895M | 599M |
| Total Debt | 564M | 596M | 578M | 399M | 318M | 97.6M | 108M | 612M | 602M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 336M | 55.3M | 73.3M | 255M | 128M | 11.8M | -64.3M | -383M | 106M | -376M | - |
| Capital Expenditure | 163M | 123M | 118M | 91.9M | 108M | 88.9M | 31.1M | 468M | 277M | 145M | 16.8M |
| Free Cash Flow | 173M | -67.8M | -44.8M | 163M | 20.6M | -77.1M | -95.4M | -852M | -171M | -521M | -51.9M |
| Ratios | |||||||||||
| ROE | 4.3% | 1.4% | -52.8% | -45.5% | 1.3% | -73.7% | -89.7% | -1,317.4% | -776.0% | -436.1% | - |
| ROA | 2.6% | 0.9% | -24.8% | -19.1% | 0.6% | -28.4% | -21.7% | -9.8% | -7.4% | -4.3% | -3.5% |
| Net Profit Margin | 7.4% | 1.9% | -59.1% | -34.3% | 1.1% | -34.0% | -22.2% | -19.1% | -14.1% | -8.1% | -5.9% |
| Debt to Equity | 0.22x | 0.24x | 0.35x | 0.35x | 0.27x | 0.15x | 0.30x | 24.27x | 18.49x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangsu Lanfeng Bio-chemical Co Ltd dividends
- Dividend yield
- 1.97%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 13, 2017
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 32.7M | 0.09 | - |
| 2024 | CNY 29.4M | 0.08 | - |
| 2023 | CNY 12.1M | 0.03 | - |
| 2022 | CNY 6.00M | 0.02 | - |
| 2021 | CNY 12.7M | 0.04 | - |
| 2020 | CNY 15.6M | 0.04 | 105.3% |
| 2019 | CNY 19.0M | 0.06 | - |
| 2018 | CNY 27.0M | 0.08 | - |
| 2017 | CNY 52.8M | 0.15 | 148.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 16:10 on Apr 27, 2012.
Who owns Jiangsu Lanfeng Bio-chemical Co Ltd
- Insiders 33.23%
- Institutions 9.72%
- Public & others 57.06%
- Shares outstanding 384M
- Free float 263M
Jiangsu Lanfeng Bio-chemical Co Ltd company profile
- Company name
- Jiangsu Lanfeng Bio-chemical Co Ltd
- Ticker
- 002513.SHE
- ISIN
- CNE100000XP5
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Dec 3, 2010
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 1,261
- Fiscal year end
- December
- Address
- No. 2 Ningxia Road, Xinyi, China, 221400
- Phone
- 86 51 6889 23437
- Website
- jslanfeng.com
About Jiangsu Lanfeng Bio-chemical Co Ltd
Jiangsu Lanfeng Bio-chemical Co.,Ltd engages in the production and processing of fungicide, insecticide, herbicide technicals and formulations, and chemical products in China and internationally. It offers carbendazim, thiophanate, fluticasone, benzoyl, cymoxanil, iprodione, imidacloprid, acetamiprid, pyrethroid, pyridaben, butylene, acetaminophen, lego, cycloazine, thiophanate-methyl, butylcarbofuran, cycloazine, sulfuric acid, and surfactants. The company is also involved in research, development, production, and sales of solar cells and module. Jiangsu Lanfeng Bio-chemical Co.,Ltd was founded in 1976 and is based in Xinyi, China.
Jiangsu Lanfeng Bio-chemical Co Ltd management
3- Mr. Zhilei LiGM & Director · born 1980
- Mr. Haijun TangDeputy GM & Board Secretary · born 1981
- Mr. Zhimin PengCFO, Deputy GM & Accounting Supervisor · born 1970